All News Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-30 EDT			5-day change	1st Jan Change
15.44 ^USD	-1.03%		-4.16%	-28.05%

04-09	UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	MT
04-03	Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	04-09	AQ
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating	04-09	MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing	04-03	MT
Denali Therapeutics Files Prospectus for Secondary Offering	03-22	MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors	02-29	CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating	02-28	MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio	02-27	MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell	02-27	MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	02-27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	02-27	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	02-27	AQ
Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP and other investors	02-26	CI
North American Morning Briefing : S&P 500 Futures -2-	02-23	DJ
Sanofi Informs Denali That Potential ALS Drug Misses Primary Endpoint of Phase 2 Study	02-20	MT
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint	02-16	DJ
Sanofi: failure of a phase 2 trial against ALS	02-16	CF
Denali Therapeutics Insider Sold Shares Worth $402,420, According to a Recent SEC Filing	02-16	MT
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	02-07	GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	02-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Denali Therapeutics Inc.

Equities

DNLI

US24823R1059

All News

Filters